A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
← catalyst calendarSponsored by Sagimet Biosciences Inc. (industry) · SGMT — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | 2025-10-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-20 | actual | The whole study's end, after follow-up |
| First posted | 2025-10-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: Denifanstat
- Drug: Resmetirom
Primary outcomes
what the primary-completion date above is the date OFArea under the concentration-time curve during a dosing interval (tau) at steady state (AUC0-tau)
measured 7 days
Maximum observed concentration at steady-state (Cmax,ss)
measured 7 days
Permalink · SGMT's whole pipeline · Catalyst calendar · Every registered study · What changed